Sleep, Dietary Melatonin Supplementation, and COVID-19


Cite item

Full Text

Abstract

Background:During the COVID-19 pandemic, people suffered from major mental health problems. These include stress, anxiety, and confusion about the existing situation of home confinement. Melatonin is a popular anti-inflammatory and antioxidant molecule sold as an over-the-counter dietary supplement.

Objective:This review discusses the indications for using melatonin in the context of the COVID-19 pandemic, including treatment.

Methods:A comprehensive search of publications was conducted in electronic databases focusing on the administration of melatonin in COVID-19.

Results:Stress has a huge negative impact on sleep routines and the quality of life of individuals. Sleep is considered an important modulator of the immune response. Thus, a lack of sleep can weaken immunity, increasing organism susceptibility to infection. For instance, shorter sleep durations are associated with a rise in suffering from the common cold. The administration of melatonin protects against viral and other pathogens and speeds clinical recovery.

Conclusion:In patients admitted to intensive care units, melatonin decreases the risks of severe complications, such as thrombosis and sepsis, and mortality rates. In addition, it is efficacious in lowering vessel permeability, depression, and sedation, and improving the quality of sleep, which could also help COVID-19 patients achieve better clinical outcomes.

About the authors

Amin Gasmi

, Société Francophone de Nutrithérapie et de Nutrigénétique Appliquée

Email: info@benthamscience.net

Yuliya Semenova

School of Medicine, Nazarbayev University

Email: info@benthamscience.net

Sadaf Noor

Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University

Email: info@benthamscience.net

Asma Benahmed

Department of Research, Académie Internationale de Médecine Dentaire Intégrative

Email: info@benthamscience.net

Geir Bjørklund

Department of Research,, Council for Nutritional and Environmental Medicine (CONEM)

Author for correspondence.
Email: info@benthamscience.net

References

  1. Cui, J.; Li, F.; Shi, Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol., 2019, 17(3), 181-192. doi: 10.1038/s41579-018-0118-9 PMID: 30531947
  2. Martín, G.V.M.; Inserra, F.; Tajer, C.D.; Mariani, J.; Ferder, L.; Reiter, R.J.; Manucha, W. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment. Life Sci., 2020, 254, 117808-117808. doi: 10.1016/j.lfs.2020.117808 PMID: 32422305
  3. Semenova, Y.; Trenina, V.; Pivina, L.; Glushkova, N.; Zhunussov, Y.; Ospanov, E.; Bjørklund, G. The lessons of COVID-19, SARS, and MERS: Implications for preventive strategies. Int. J. Healthc. Manag., 2022, 15(4), 314-324. doi: 10.1080/20479700.2022.2051126
  4. Semenova, Y.; Kalmatayeva, Z.; Oshibayeva, A.; Mamyrbekova, S.; Kudirbekova, A.; Nurbakyt, A.; Baizhaxynova, A.; Colet, P.; Glushkova, N.; Ivankov, A.; Sarria-Santamera, A. Seropositivity of SARS-CoV-2 in the population of Kazakhstan: A nationwide laboratory-based surveillance. Int. J. Environ. Res. Public Health, 2022, 19(4), 2263. doi: 10.3390/ijerph19042263 PMID: 35206453
  5. Greenberg, N.; Docherty, M.; Gnanapragasam, S.; Wessely, S. Managing mental health challenges faced by healthcare workers during COVID-19 pandemic. BMJ, 2020, 368, m1211. doi: 10.1136/bmj.m1211 PMID: 32217624
  6. Wang, G.; Zhang, Y.; Zhao, J.; Zhang, J.; Jiang, F. Mitigate the effects of home confinement on children during the COVID-19 outbreak. Lancet, 2020, 395(10228), 945-947. doi: 10.1016/S0140-6736(20)30547-X PMID: 32145186
  7. Cohen, S.; Doyle, W.J.; Alper, C.M.; Janicki-Deverts, D.; Turner, R.B. Sleep habits and susceptibility to the common cold. Arch. Intern. Med., 2009, 169(1), 62-67. doi: 10.1001/archinternmed.2008.505 PMID: 19139325
  8. Glaser, R.; Kiecolt-Glaser, J.K. Stress-induced immune dysfunction: Implications for health. Nat. Rev. Immunol., 2005, 5(3), 243-251. doi: 10.1038/nri1571 PMID: 15738954
  9. Besedovsky, L.; Lange, T.; Born, J. Sleep and immune function. Pflugers Arch., 2012, 463(1), 121-137. doi: 10.1007/s00424-011-1044-0 PMID: 22071480
  10. Wright, J.H.; Caudill, R. Remote treatment delivery in response to the COVID-19 pandemic. Psychother. Psychosom., 2020, 89(3), 130-132. doi: 10.1159/000507376 PMID: 32213775
  11. Reiter, R.J.; Ma, Q.; Sharma, R. Melatonin in mitochondria: Mitigating clear and present dangers. Physiology, 2020, 35(2), 86-95. doi: 10.1152/physiol.00034.2019 PMID: 32024428
  12. Benington, J.H.; Craig Heller, H. Restoration of brain energy metabolism as the function of sleep. Prog. Neurobiol., 1995, 45(4), 347-360. doi: 10.1016/0301-0082(94)00057-O PMID: 7624482
  13. Mackiewicz, M.; Shockley, K.R.; Romer, M.A.; Galante, R.J.; Zimmerman, J.E.; Naidoo, N.; Baldwin, D.A.; Jensen, S.T.; Churchill, G.A.; Pack, A.I. Macromolecule biosynthesis: A key function of sleep. Physiol. Genomics, 2007, 31(3), 441-457. doi: 10.1152/physiolgenomics.00275.2006 PMID: 17698924
  14. Dimitrov, S.; Lange, T.; Nohroudi, K.; Born, J. Number and function of circulating human antigen presenting cells regulated by sleep. Sleep, 2007, 30(4), 401-411. doi: 10.1093/sleep/30.4.401 PMID: 17520784
  15. Yehuda, S.; Sredni, B.; Carasso, R.L.; Kenigsbuch-Sredni, D. REM sleep deprivation in rats results in inflammation and interleukin-17 elevation. J Interferon Cytokine Res, 2009, 29(7), 393-398. doi: 10.1089/jir.2008.0080 PMID: 19450150
  16. Zager, A.; Andersen, M.L.; Ruiz, F.S.; Antunes, I.B.; Tufik, S. Effects of acute and chronic sleep loss on immune modulation of rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 293(1), R504-R509. doi: 10.1152/ajpregu.00105.2007 PMID: 17409265
  17. Ibarra-Coronado, E.G.; Pantaleón-Martínez, A.M.; Velazquéz-Moctezuma, J.; Prospéro-García, O.; Méndez-Díaz, M.; Pérez-Tapia, M.; Pavón, L.; Morales-Montor, J. The bidirectional relationship between sleep and immunity against infections. J. Immunol. Res., 2015, 2015, 1-14. doi: 10.1155/2015/678164 PMID: 26417606
  18. Hurtado-Alvarado, G.; Domínguez-Salazar, E.; Pavon, L.; Velázquez-Moctezuma, J.; Gómez-González, B. Blood-brain barrier disruption induced by chronic sleep loss: low-grade inflammation may be the link. J. Immunol. Res., 2016, 2016, 1-15. doi: 10.1155/2016/4576012 PMID: 27738642
  19. Fang, J.; Sanborn, C.K.; Renegar, K.B.; Majde, J.A.; Krueger, J.M. Influenza viral infections enhance sleep in mice. Exp. Biol. Med., 1995, 210(3), 242-252. doi: 10.3181/00379727-210-43945 PMID: 8539262
  20. Fang, I.; Tooley, D.; Gatewood, C.; Renegar, K.B.; Majde, J.A.; Krueger, J.M. Differential effects of total and upper airway influenza viral infection on sleep in mice. Sleep, 1996, 19(4), 337-342. PMID: 8776792
  21. Horváth, A.; Papp, A.; Szűcs, A. Progress in elucidating the pathophysiological basis of nonrapid eye movement parasomnias: not yet informing therapeutic strategies. Nat. Sci. Sleep, 2016, 8, 73-79. PMID: 27022307
  22. Cooke, G.S.; Hill, A.V.S. Genetics of susceptibitlity to human infectious disease. Nat. Rev. Genet., 2001, 2(12), 967-977. doi: 10.1038/35103577 PMID: 11733749
  23. Hill, A.V.S. The genomics and genetics of human infectious disease susceptibility. Annu. Rev. Genomics Hum. Genet., 2001, 2(1), 373-400. doi: 10.1146/annurev.genom.2.1.373 PMID: 11701655
  24. Trammell, R.A.; Liberati, T.A.; Toth, L.A. Host genetic background and the innate inflammatory response of lung to influenza virus. Microbes Infect., 2012, 14(1), 50-58. doi: 10.1016/j.micinf.2011.08.008 PMID: 21920449
  25. Tuite, A.; Gros, P. The impact of genomics on the analysis of host resistance to infectious disease. Microbes Infect., 2006, 8(6), 1647-1653. doi: 10.1016/j.micinf.2005.11.016 PMID: 16697229
  26. Toth, L.; Rehg, J.E.; Webster, R.G. Strain differences in sleep and other pathophysiological sequelae of influenza virus infection in naive and immunized mice. J. Neuroimmunol., 1995, 58(1), 89-99. doi: 10.1016/0165-5728(94)00193-R PMID: 7730450
  27. Dahan, V.; Kimoff, R.J.; Petrof, B.J.; Benedetti, A.; Diorio, D.; Trojan, D.A. Sleep-disordered breathing in fatigued postpoliomyelitis clinic patients. Arch. Phys. Med. Rehabil., 2006, 87(10), 1352-1356. doi: 10.1016/j.apmr.2006.07.256 PMID: 17023245
  28. Silva, T.M.; Moreira, G.A.; Quadros, A.A.J.; Pradella-Hallinan, M.; Tufik, S.; Oliveira, A.S.B. Analysis of sleep characteristics in post-polio syndrome patients. Arq. Neuropsiquiatr., 2010, 68(4), 535-540. doi: 10.1590/S0004-282X2010000400011 PMID: 20730305
  29. Steljes, D.G.; Kryger, M.H.; Kirk, B.W.; Millar, T.W. Sleep in postpolio syndrome. Chest, 1990, 98(1), 133-140. doi: 10.1378/chest.98.1.133 PMID: 2361379
  30. Darko, D.F.; McCutchan, J.A.; Kripke, D.F.; Gillin, J.C.; Golshan, S. Fatigue, sleep disturbance, disability, and indices of progression of HIV infection. Am. J. Psychiatry, 1992, 149(4), 514-520. doi: 10.1176/ajp.149.4.514 PMID: 1554037
  31. Kanmogne, G.D.; Fonsah, J.Y.; Umlauf, A.; Moul, J.; Doh, R.F.; Kengne, A.M.; Tang, B.; Tagny, C.T.; Nchindap, E.; Kenmogne, L.; Franklin, D.; Njamnshi, D.M.; Mbanya, D.; Njamnshi, A.K.; Heaton, R.K. Attention/working memory, learning and memory in adult cameroonians: Normative data, effects of HIV infection and viral genotype. J. Int. Neuropsychol. Soc., 2020, 26(6), 607-623. doi: 10.1017/S1355617720000120 PMID: 32066518
  32. Chung, W.S.; Lin, H.H.; Cheng, N.C. The incidence and risk of herpes zoster in patients with sleep disorders. Medicine, 2016, 95(11), e2195. doi: 10.1097/MD.0000000000002195 PMID: 26986095
  33. Gohier, B.; Goeb, J.L.; Rannou-Dubas, K.; Fouchard, I.; Calès, P.; Garré, J.B. Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients. World J. Biol. Psychiatry, 2003, 4(3), 115-118. doi: 10.1080/15622970310029904 PMID: 12872204
  34. Thein, H.H.; Maruff, P.; Krahn, M.; Kaldor, J.M.; Koorey, D.J.; Brew, B.J.; Dore, G.J. Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)- monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Med., 2007, 8(3), 192-202. doi: 10.1111/j.1468-1293.2007.00452.x PMID: 17461864
  35. Sockalingam, S.; Abbey, S.E.; Alosaimi, F.; Novak, M. A review of sleep disturbance in hepatitis C. J. Clin. Gastroenterol., 2010, 44(1), 38-45. doi: 10.1097/MCG.0b013e3181b314ea PMID: 19730115
  36. Huang, Y.; Zhao, N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: A web-based cross-sectional survey. Psychiatry Res., 2020, 288, 112954-112954. doi: 10.1016/j.psychres.2020.112954 PMID: 32325383
  37. Torales, J.; O’Higgins, M.; Castaldelli-Maia, J.M.; Ventriglio, A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int. J. Soc. Psychiatry, 2020, 66(4), 317-320. doi: 10.1177/0020764020915212 PMID: 32233719
  38. Firth, J.; Torous, J. Multidisciplinary research priorities for the COVID-19 pandemic. Lancet Psychiatry, 2020, 7(7), e39. doi: 10.1016/S2215-0366(20)30251-0 PMID: 32563314
  39. Calvo-Sanz, J.; Tapia-Ayuga, C.E. Blue light emission spectra of popular mobile devices: The extent of user protection against melatonin suppression by built-in screen technology and light filtering software systems. Chronobiol. Int., 2020, 37(7), 1016-1022. doi: 10.1080/07420528.2020.1781149 PMID: 32649241
  40. Horenstein, A.; Morrison, A.S.; Goldin, P.; ten Brink, M.; Gross, J.J.; Heimberg, R.G. Sleep quality and treatment of social anxiety disorder. Anxiety Stress Coping, 2019, 32(4), 387-398. doi: 10.1080/10615806.2019.1617854 PMID: 31082285
  41. Hempler, N.F.; Joensen, L.E.; Willaing, I. Relationship between social network, social support and health behaviour in people with type 1 and type 2 diabetes: cross-sectional studies. BMC Public Health, 2016, 16(1), 198. doi: 10.1186/s12889-016-2819-1 PMID: 26926867
  42. Utz, S.; Breuer, J. The relationship between use of social network sites, online social support, and well-being. J. Media Psychol., 2017, 29(3), 115-125. doi: 10.1027/1864-1105/a000222 PMID: 29147141
  43. Alvaro, P.K.; Roberts, R.M.; Harris, J.K. A systematic review assessing bidirectionality between sleep disturbances, anxiety, and depression. Sleep, 2013, 36(7), 1059-1068. doi: 10.5665/sleep.2810 PMID: 23814343
  44. Cardinali, D.P.; Srinivasan, V.; Brzezinski, A.; Brown, G.M. Melatonin and its analogs in insomnia and depression. J. Pineal Res., 2012, 52(4), 365-375. doi: 10.1111/j.1600-079X.2011.00962.x PMID: 21951153
  45. van Santen, A.; Vreeburg, S.A.; Van der Does, A.J.W.; Spinhoven, P.; Zitman, F.G.; Penninx, B.W.J.H. Psychological traits and the cortisol awakening response: Results from the Netherlands study of depression and anxiety. Psychoneuroendocrinology, 2011, 36(2), 240-248. doi: 10.1016/j.psyneuen.2010.07.014 PMID: 20724080
  46. Deng, J.; Zhou, F.; Hou, W.; Silver, Z.; Wong, C.Y.; Chang, O.; Huang, E.; Zuo, Q.K. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann. N. Y. Acad. Sci., 2021, 1486(1), 90-111. doi: 10.1111/nyas.14506 PMID: 33009668
  47. Donzella, S.M.; Kohler, L.N.; Crane, T.E.; Jacobs, E.T.; Ernst, K.C.; Bell, M.L.; Catalfamo, C.J.; Begay, R.; Pogreba-Brown, K.; Farland, L.V. COVID-19 infection, the COVID-19 pandemic, and changes in sleep. Front. Public Health, 2022, 9, 795320. doi: 10.3389/fpubh.2021.795320 PMID: 35174134
  48. Pellitteri, G.; Surcinelli, A.; De Martino, M.; Fabris, M.; Janes, F.; Bax, F.; Marini, A.; Milanic, R.; Piani, A.; Isola, M.; Gigli, G.L.; Valente, M. Sleep alterations following COVID-19 are associated with both neuroinflammation and psychological disorders, although at different times. Front. Neurol., 2022, 13, 929480. doi: 10.3389/fneur.2022.929480 PMID: 36062000
  49. Abdelghani, M.; Alsadik, M.; Abdelmoaty, A.; Atwa, S.; Said, A.; Hassan, M. Sleep disturbances following recovery from COVID-19: A comparative cross-sectional study in Egypt. East. Mediterr. Health J., 2022, 28(1), 14-22. doi: 10.26719/emhj.22.006 PMID: 35165874
  50. El Sayed, S.; Gomaa, S.; Shokry, D.; Kabil, A.; Eissa, A. Sleep in post-COVID-19 recovery period and its impact on different domains of quality of life. Egypt. J. Neurol. Psychiat. Neurosurg., 2021, 57(1), 172. doi: 10.1186/s41983-021-00429-7 PMID: 34924750
  51. Camargo-Martínez, W.; Lozada-Martínez, I.; Escobar-Collazos, A.; Navarro-Coronado, A.; Moscote-Salazar, L.; Pacheco-Hernández, A.; Janjua, T.; Bosque-Varela, P. Post-COVID-19 neurological syndrome: Implications for sequelae’s treatment. J. Clin. Neurosci., 2021, 88, 219-225. doi: 10.1016/j.jocn.2021.04.001 PMID: 33992187
  52. Zildzic, M.; Salihefendic, D.; Masic, I. Non-pharmacological measures in the prevention and treatment of COVID-19 infection. Med. Arh., 2021, 75(4), 307-312. doi: 10.5455/medarh.2021.75.307-312 PMID: 34759453
  53. Ekhtiari, H.; Rezapour, T.; Aupperle, R.L.; Paulus, M.P. Neuroscience-informed psychoeducation for addiction medicine: A neurocognitive perspective. Prog. Brain Res., 2017, 235, 239-264. doi: 10.1016/bs.pbr.2017.08.013 PMID: 29054291
  54. DeRubeis, R.J.; Hollon, S.D.; Amsterdam, J.D.; Shelton, R.C.; Young, P.R.; Salomon, R.M.; O’Reardon, J.P.; Lovett, M.L.; Gladis, M.M.; Brown, L.L.; Gallop, R. Cognitive therapy vs. medications in the treatment of moderate to severe depression. Arch. Gen. Psychiatry, 2005, 62(4), 409-416. doi: 10.1001/archpsyc.62.4.409 PMID: 15809408
  55. Thoma, N.; Pilecki, B.; McKay, D. Contemporary cognitive behavior therapy: A review of theory, history, and evidence. Psychodyn. Psychiatry, 2015, 43(3), 423-461. doi: 10.1521/pdps.2015.43.3.423 PMID: 26301761
  56. Brewin, C.R. Theoretical foundations of cognitive-behavior therapy for anxiety and depression. Annu. Rev. Psychol., 1996, 47(1), 33-57. doi: 10.1146/annurev.psych.47.1.33 PMID: 8624137
  57. Benjamin, C.L.; Puleo, C.M.; Settipani, C.A.; Brodman, D.M.; Edmunds, J.M.; Cummings, C.M.; Kendall, P.C. History of cognitive-behavioral therapy in youth. Child Adolesc. Psychiatr. Clin. N. Am., 2011, 20(2), 179-189. doi: 10.1016/j.chc.2011.01.011 PMID: 21440849
  58. McKay, D.; Sookman, D.; Neziroglu, F.; Wilhelm, S.; Stein, D.J.; Kyrios, M.; Matthews, K.; Veale, D. Efficacy of cognitive-behavioral therapy for obsessive–compulsive disorder. Psychiatry Res., 2015, 225(3), 236-246. doi: 10.1016/j.psychres.2014.11.058 PMID: 25613661
  59. Zhu, Z.; Zhang, L.; Jiang, J.; Li, W.; Cao, X.; Zhou, Z.; Zhang, T.; Li, C. Comparison of psychological placebo and waiting list control conditions in the assessment of cognitive behavioral therapy for the treatment of generalized anxiety disorder: A meta-analysis. Shanghai Jingshen Yixue, 2014, 26(6), 319-331. PMID: 25642106
  60. Johansson, R.; Andersson, G. Internet-based psychological treatments for depression. Expert Rev. Neurother., 2012, 12(7), 861-870. doi: 10.1586/ern.12.63 PMID: 22853793
  61. Altena, E.; Micoulaud-Franchi, J.A.; Geoffroy, P.A.; Sanz-Arigita, E.; Bioulac, S.; Philip, P. The bidirectional relation between emotional reactivity and sleep: From disruption to recovery. Behav. Neurosci., 2016, 130(3), 336-350. doi: 10.1037/bne0000128 PMID: 26866361
  62. Morin, C.M.; Inoue, Y.; Kushida, C.; Poyares, D.; Winkelman, J. Endorsement of European guideline for the diagnosis and treatment of insomnia by the World Sleep Society. Sleep Med., 2021, 81, 124-126. doi: 10.1016/j.sleep.2021.01.023 PMID: 33667998
  63. Baglioni, C.; Altena, E.; Bjorvatn, B.; Blom, K.; Bothelius, K.; Devoto, A.; Espie, C.A.; Frase, L.; Gavriloff, D.; Tuuliki, H.; Hoflehner, A.; Högl, B.; Holzinger, B.; Järnefelt, H.; Jernelöv, S.; Johann, A.F.; Lombardo, C.; Nissen, C.; Palagini, L.; Peeters, G.; Perlis, M.L.; Posner, D.; Schlarb, A.; Spiegelhalder, K.; Wichniak, A.; Riemann, D. The European academy for cognitive behavioural therapy for insomnia: An initiative of the european insomnia network to promote implementation and dissemination of treatment. J. Sleep Res., 2019, 29. PMID: 31856367
  64. Morin, C.M.; Vallières, A.; Guay, B.; Ivers, H.; Savard, J.; Mérette, C.; Bastien, C.; Baillargeon, L. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA, 2009, 301(19), 2005-2015. doi: 10.1001/jama.2009.682 PMID: 19454639
  65. Randall, C.; Nowakowski, S.; Ellis, J.G. Managing acute insomnia in prison: Evaluation of a "one-shot" cognitive behavioral therapy for insomnia (CBT-I) intervention. Behav. Sleep Med., 2019, 17(6), 827-836. doi: 10.1080/15402002.2018.1518227 PMID: 30289290
  66. Shah, S.M.A.; Mohammad, D.; Qureshi, M.F.H.; Abbas, M.Z.; Aleem, S. Prevalence, psychological responses and associated correlates of depression, anxiety and stress in a global population, during the coronavirus disease (COVID-19) pandemic. Community Ment. Health J., 2020, 1-10. PMID: 33108569
  67. Bastien, C.H.; Morin, C.M.; Ouellet, M.C.; Blais, F.C.; Bouchard, S. Cognitive-behavioral therapy for insomnia: Comparison of individual therapy, group therapy, and telephone consultations. J. Consult. Clin. Psychol., 2004, 72(4), 653-659. doi: 10.1037/0022-006X.72.4.653 PMID: 15301650
  68. Fuller, K.H.; Waters, W.F.; Binks, P.G.; Anderson, T. Generalized anxiety and sleep architecture: A polysomnographic investigation. Sleep, 1997, 20(5), 370-376. doi: 10.1093/sleep/20.5.370 PMID: 9381061
  69. Liu, N.; Zhang, F.; Wei, C.; Jia, Y.; Shang, Z.; Sun, L.; Wu, L.; Sun, Z.; Zhou, Y.; Wang, Y.; Liu, W. Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: Gender differences matter. Psychiatry Res., 2020, 287, 112921-112921. doi: 10.1016/j.psychres.2020.112921 PMID: 32240896
  70. Kim, H.; Hegde, S.; LaFiura, C.; Raghavan, M.; Luong, E.; Cheng, S.; Rebholz, C.M.; Seidelmann, S.B. COVID-19 illness in relation to sleep and burnout. BMJ Nutrition, Prevention & Health, 2021. doi: 10.1136/bmjnph-2021-000228
  71. Hofmann, S.G.; Gómez, A.F. Mindfulness-based interventions for anxiety and depression. Psychiatr. Clin. North Am., 2017, 40(4), 739-749. doi: 10.1016/j.psc.2017.08.008 PMID: 29080597
  72. Creswell, J.D. Mindfulness interventions. Annu. Rev. Psychol., 2017, 68, 491-516. doi: 10.1146/annurev-psych-042716-051139 PMID: 27687118
  73. Carlson, L.E. Mindfulness-based interventions for physical conditions: A narrative review evaluating levels of evidence. ISRN Psychiatry, 2012, 2012, 1-21. doi: 10.5402/2012/651583 PMID: 23762768
  74. Sanada, K.; Montero-Marin, J.; Barceló-Soler, A.; Ikuse, D.; Ota, M.; Hirata, A.; Yoshizawa, A.; Hatanaka, R.; Valero, M.S.; Demarzo, M.; Campayo, J.G.; Iwanami, A. Effects of mindfulness-based interventions on biomarkers and low-grade inflammation in patients with psychiatric disorders: A meta-analytic review. Int. J. Mol. Sci., 2020, 21(7), 2484. doi: 10.3390/ijms21072484 PMID: 32260096
  75. Roque-Lopez, S.; Llanez-Anaya, E.; Álvarez-López, M.J.; Everts, M.; Fernández, D.; Davidson, R.J.; Kaliman, P. Mental health benefits of a 1-week intensive multimodal group program for adolescents with multiple adverse childhood experiences. Child Abuse Negl., 2021, 122, 105349. doi: 10.1016/j.chiabu.2021.105349 PMID: 34628152
  76. Juul, L.; Pallesen, K.J.; Bjerggaard, M.; Nielsen, C.; Fjorback, L.O. A pilot randomised trial comparing a mindfulness-based stress reduction course, a locally-developed stress reduction intervention and a waiting list control group in a real-life municipal health care setting. BMC Public Health, 2020, 20(1), 409. doi: 10.1186/s12889-020-08470-6 PMID: 32228533
  77. Pascoe, M.C.; Thompson, D.R.; Jenkins, Z.M.; Ski, C.F. Mindfulness mediates the physiological markers of stress: Systematic review and meta-analysis. J. Psychiatr. Res., 2017, 95, 156-178. doi: 10.1016/j.jpsychires.2017.08.004 PMID: 28863392
  78. Chadi, N.; Weisbaum, E.; Vo, D.X.; Ahola Kohut, S. Mindfulness-based interventions for adolescents: Time to consider telehealth. J. Altern. Complement. Med., 2020, 26(3), 172-175. doi: 10.1089/acm.2019.0302 PMID: 31765222
  79. DeVries, A.C.; Glasper, E.R.; Detillion, C. E. Social modulation of stress responses. Physiol Behav, 2003, 79, 399-407. doi: 10.1016/s0031-9384(03)00152-5 PMID: 12954434
  80. Xiao, H.; Zhang, Y.; Kong, D.; Li, S.; Yang, N. Social capital and sleep quality in individuals who self-isolated for 14 days during the coronavirus disease 2019 (COVID-19) outbreak in january 2020 in China. Med. Sci. Monit., 2020, 26, e923921. doi: 10.12659/MSM.923921 PMID: 32194290
  81. Basner, M.; Fomberstein, K.M.; Razavi, F.M.; Banks, S.; William, J.H.; Rosa, R.R.; Dinges, D.F. American time use survey: Sleep time and its relationship to waking activities. Sleep, 2007, 30(9), 1085-1095. doi: 10.1093/sleep/30.9.1085 PMID: 17910380
  82. Kent de Grey, R.G.; Uchino, B.N.; Trettevik, R.; Cronan, S.; Hogan, J.N. Social support and sleep: A meta-analysis. Health Psychol., 2018, 37(8), 787-798. doi: 10.1037/hea0000628 PMID: 29809022
  83. Peng, Y.; Ao, M.; Dong, B.; Jiang, Y.; Yu, L.; Chen, Z.; Hu, C.; Xu, R. Anti-inflammatory effects of curcumin in the inflammatory diseases: Status, limitations and countermeasures. Drug Des. Devel. Ther., 2021, 15, 4503-4525. doi: 10.2147/DDDT.S327378 PMID: 34754179
  84. Xu, Y.; Ku, B.; Cui, L.; Li, X.; Barish, P.A.; Foster, T.C.; Ogle, W.O. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res., 2007, 1162, 9-18. doi: 10.1016/j.brainres.2007.05.071 PMID: 17617388
  85. Nouri-Vaskeh, M.; Afshan, H.; Malek Mahdavi, A.; Alizadeh, L.; Fan, X.; Zarei, M. Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial. Complement. Ther. Med., 2020, 49, 102351. doi: 10.1016/j.ctim.2020.102351 PMID: 32147077
  86. Aguiar, S.; Borowski, T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res., 2013, 16(4), 313-326. doi: 10.1089/rej.2013.1431 PMID: 23772955
  87. Simpson, T.; Pase, M.; Stough, C. Bacopa monnieri as an antioxidant therapy to reduce oxidative stress in the aging brain. Evid. Based Complement. Alternat. Med., 2015, 2015, 1-9. doi: 10.1155/2015/615384 PMID: 26413126
  88. Lopresti, A.L.; Smith, S.J.; Ali, S.; Metse, A.P.; Kalns, J.; Drummond, P.D. Effects of a Bacopa monnieri extract (Bacognize®) on stress, fatigue, quality of life and sleep in adults with self-reported poor sleep: A randomised, double-blind, placebo-controlled study. J. Funct. Foods, 2021, 85, 104671. doi: 10.1016/j.jff.2021.104671
  89. Shetty, S.K.; Rao, P.N.; U, S.; Raj, A.; Ks, S.; Sv, S. The effect of brahmi (Bacopa monnieri (L.) Pennell) on depression, anxiety and stress during COVID-19. Eur. J. Integr. Med., 2021, 48, 101898. doi: 10.1016/j.eujim.2021.101898
  90. Mancuso, C.; Santangelo, R. Panax ginseng and Panax quinquefolius: From pharmacology to toxicology. Food Chem. Toxicol., 2017, 107(Pt A), 362-372. doi: 10.1016/j.fct.2017.07.019 PMID: 28698154
  91. Yi, Y.S. Potential benefits of ginseng against COVID-19 by targeting inflammasomes. J. Ginseng Res., 2022, 46(6), 722-730. doi: 10.1016/j.jgr.2022.03.008 PMID: 35399195
  92. Jeong Han, H.; Yun Kim, H.; Joon Choi, J.; Ahn, S.Y.; Lee, S.H.; Oh, K.W.; Kim, S.Y. Effects of red ginseng extract on sleeping behaviors in human volunteers. J. Ethnopharmacol., 2013, 149(2), 597-599. doi: 10.1016/j.jep.2013.07.005 PMID: 23872254
  93. Hardeland, R. Melatonin and inflammation-story of a double-edged blade. J. Pineal Res., 2018, 65(4), e12525. doi: 10.1111/jpi.12525 PMID: 30242884
  94. Reiter, R.J.; Tan, D.X.; Mayo, J.C.; Sainz, R.M.; Leon, J.; Czarnocki, Z. Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans. Acta Biochim. Pol., 2003, 50(4), 1129-1146. doi: 10.18388/abp.2003_3637 PMID: 14740000
  95. Sinha, B.; Wu, Q.; Li, W.; Tu, Y.; Sirianni, A.C.; Chen, Y.; Jiang, J.; Zhang, X.; Chen, W.; Zhou, S.; Reiter, R.J.; Manning, S.M.; Patel, N.J.; Aziz-Sultan, A.M.; Inder, T.E.; Friedlander, R.M.; Fu, J.; Wang, X. Protection of melatonin in experimental models of newborn hypoxic-ischemic brain injury through MT1 receptor. J. Pineal Res., 2018, 64(1), e12443. doi: 10.1111/jpi.12443 PMID: 28796402
  96. Wurtman, R.J.; Axelrod, J.; Phillips, L.S. Melatonin synthesis in the pineal gland: control by light. Science, 1963, 142(3595), 1071-1073. doi: 10.1126/science.142.3595.1071 PMID: 14068225
  97. Zisapel, N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br. J. Pharmacol., 2018, 175(16), 3190-3199. doi: 10.1111/bph.14116 PMID: 29318587
  98. Juricek, L.; Xavier, C. The aryl hydrocarbon receptor and the nervous system. Int. J. Mol. Sci., 2018, 19(9), 25049. doi: 10.3390/ijms19092504
  99. Lee, K.; Hwang, O.J.; Back, K. Rice N-acetylserotonin deacetylase regulates melatonin levels in transgenic rice. Melatonin Res., 2020, 3(1), 32-42. doi: 10.32794/mr11250046
  100. Coto-Montes, A.; Boga, J.; Tan, D.; Reiter, R. Melatonin as a potential agent in the treatment of sarcopenia. Int. J. Mol. Sci., 2016, 17(10), 1771. doi: 10.3390/ijms17101771 PMID: 27783055
  101. Sieck, G.C. Physiology in perspective: Physiological systems respond to time. Physiology , 2020, 35(2), 84-85. doi: 10.1152/physiol.00002.2020 PMID: 32024427
  102. Huang, S.H.; Cao, X.J.; Liu, W.; Shi, X.Y.; Wei, W. Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice. J. Pineal Res., 2010, 48(2), 109-116. doi: 10.1111/j.1600-079X.2009.00733.x PMID: 20070490
  103. Huang, S.H.; Cao, X.J.; Wei, W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophages. J. Pineal. Res.2008; 45(1): 93-100. doi: 10.1111/j.1600-079X.2008.00560.x.
  104. Miller, S.C.; Pandi, P.S.R.; Esquifino, A.I.; Cardinali, D.P.; Maestroni, G.J.M. The role of melatonin in immuno-enhancement: Potential application in cancer. Int. J. Exp. Pathol., 2006, 87(2), 81-87. doi: 10.1111/j.0959-9673.2006.00474.x PMID: 16623752
  105. Zhang, R.; Wang, X.; Ni, L.; Di, X.; Ma, B.; Niu, S.; Liu, C.; Reiter, R.J. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci., 2020, 250, 117583-117583. doi: 10.1016/j.lfs.2020.117583 PMID: 32217117
  106. Wang, Q.L.; Yang, L.; Peng, Y.; Gao, M.; Yang, M.S.; Xing, W.; Xiao, X.Z. Ginsenoside Rg1 regulates SIRT1 to ameliorate sepsis-induced lung inflammation and injury viainhibiting endoplasmic reticulum stress and inflammation. Mediators Inflamm., 2019, 2019, 1-10. doi: 10.1155/2019/6453296 PMID: 30918470
  107. Sun, C.K.; Lee, F.Y.; Kao, Y.H.; Chiang, H.J.; Sung, P.H.; Tsai, T.H.; Lin, Y.C.; Leu, S.; Wu, Y.C.; Lu, H.I.; Chen, Y.L.; Chung, S.Y.; Su, H.L.; Yip, H.K. Systemic combined melatonin-mitochondria treatment improves acute respiratory distress syndrome in the rat. J. Pineal Res., 2015, 58(2), 137-150. doi: 10.1111/jpi.12199 PMID: 25491480
  108. Shang, Y.; Xu, S.P.; Wu, Y.; Jiang, Y.X.; Wu, Z.Y.; Yuan, S.Y.; Yao, S.L. Melatonin reduces acute lung injury in endotoxemic rats. Chin. Med. J., 2009, 122(12), 1388-1393. PMID: 19567158
  109. Pedrosa, A.M.C.; Weinlich, R.; Mognol, G.P.; Robbs, B.K.; Viola, J.P.B.; Campa, A.; Amarante-Mendes, G.P. Melatonin protects CD4+ T cells from activation-induced cell death by blocking NFAT-mediated CD95 ligand upregulation. J. Immunol., 2010, 184(7), 3487-3494. doi: 10.4049/jimmunol.0902961 PMID: 20181888
  110. Habtemariam, S.; Daglia, M.; Sureda, A.; Selamoglu, Z.; Fuat, G.M.; Mohammad, NS. Melatonin and respiratory diseases: A review. Curr. Top. Med. Chem., 2016, 17(4), 467-488. doi: 10.2174/1568026616666160824120338 PMID: 27558675
  111. Mańka, S.; Majewska, E. Immunoregulatory action of melatonin. The mechanism of action and the effect on inflammatory cells. Postepy Hig. Med. Dosw., 2016, 70(0), 1059-1067. doi: 10.5604/17322693.1221001 PMID: 27708210
  112. Korkmaz, A.; Reiter, R.J.; Topal, T.; Manchester, L.C.; Oter, S.; Tan, D.X. Melatonin: an established antioxidant worthy of use in clinical trials. Mol. Med., 2009, 15(1-2), 43-50. doi: 10.2119/molmed.2008.00117 PMID: 19011689
  113. Shirey, K.A.; Lai, W.; Scott, A.J.; Lipsky, M.; Mistry, P.; Pletneva, L.M.; Karp, C.L.; McAlees, J.; Gioannini, T.L.; Weiss, J.; Chen, W.H.; Ernst, R.K.; Rossignol, D.P.; Gusovsky, F.; Blanco, J.C.G.; Vogel, S.N. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature, 2013, 497(7450), 498-502. doi: 10.1038/nature12118 PMID: 23636320
  114. Sui, X. Inhibition of the NF-κB signaling pathway on endothelial cell function and angiogenesis in mice with acute cerebral infarction. J. Biol. Regul. Homeost. Agents, 2019, 33(2), 375-384. PMID: 30945527
  115. Zhao, Y.; Wang, H.; Chen, W.; Chen, L.; Liu, D.; Wang, X.; Wang, X. Melatonin attenuates white matter damage after focal brain ischemia in rats by regulating the TLR4/NF-κB pathway. Brain Res. Bull., 2019, 150, 168-178. doi: 10.1016/j.brainresbull.2019.05.019 PMID: 31158461
  116. Cuzzocrea, S.; Russel, J.R. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur J Pharmacol, 2001, 426(1-2), 1-10. doi: 10.1016/s0014-2999(01)01175-x PMID: 11525764
  117. Gitto, E.; Karbownik, M.; Reiter, R.J.; Tan, D.X.; Cuzzocrea, S.; Chiurazzi, P.; Cordaro, S.; Corona, G.; Trimarchi, G.; Barberi, I. Effects of melatonin treatment in septic newborns. Pediatr. Res., 2001, 50(6), 756-760. doi: 10.1203/00006450-200112000-00021 PMID: 11726736
  118. Mundigler, G.; Delle-Karth, G.; Koreny, M.; Zehetgruber, M.; Steindl-Munda, P.; Marktl, W.; Fertl, L.; Siostrzonek, P. Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit. Care Med., 2002, 30(3), 536-540. doi: 10.1097/00003246-200203000-00007 PMID: 11990911
  119. Tamura, D.Y.; Moore, E.E.; Partrick, D.A.; Johnson, J.L.; Offner, P.J.; Silliman, C.C. Acute hypoxemia in humans enhances the neutrophil inflammatory response. Shock, 2002, 17(4), 269-273. doi: 10.1097/00024382-200204000-00005 PMID: 11954825
  120. Gitto, E.; Reiter, R.J.; Sabatino, G.; Buonocore, G.; Romeo, C.; Gitto, P.; Buggé, C.; Trimarchi, G.; Barberi, I. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J. Pineal Res., 2005, 39(3), 287-293. doi: 10.1111/j.1600-079X.2005.00251.x PMID: 16150110
  121. Bazyar, H.; Gholinezhad, H.; Moradi, L.; Salehi, P.; Abadi, F.; Ravanbakhsh, M.; Zare Javid, A. The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled trial. Inflammopharmacology, 2019, 27(1), 67-76. doi: 10.1007/s10787-018-0539-0 PMID: 30328031
  122. Sánchez-López, A.L.; Ortiz, G.G.; Pacheco-Moises, F.P.; Mireles-Ramírez, M.A.; Bitzer-Quintero, O.K.; Delgado-Lara, D.L.C.; Ramírez-Jirano, L.J.; Velázquez-Brizuela, I.E. Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Arch. Med. Res., 2018, 49(6), 391-398. doi: 10.1016/j.arcmed.2018.12.004 PMID: 30595364
  123. Kücükakin, B.; Lykkesfeldt, J.; Nielsen, H.J.; Reiter, R.J.; Rosenberg, J.; Gögenur, I. Utility of melatonin to treat surgical stress after major vascular surgery – a safety study. J. Pineal Res., 2008, 44(4), 426-431. doi: 10.1111/j.1600-079X.2007.00545.x PMID: 18205732
  124. Zhao, Z.; Lu, C.; Li, T.; Wang, W.; Ye, W.; Zeng, R.; Ni, L.; Lai, Z.; Wang, X.; Liu, C. The protective effect of melatonin on brain ischemia and reperfusion in rats and humans: In vivo assessment and a randomized controlled trial. J. Pineal Res., 2018, 65(4), e12521. doi: 10.1111/jpi.12521 PMID: 30098076
  125. Zarezadeh, M.; Khorshidi, M.; Emami, M.; Janmohammadi, P.; Kord-varkaneh, H.; Mousavi, S.M.; Mohammed, S.H.; Saedisomeolia, A.; Alizadeh, S. Melatonin supplementation and pro-inflammatory mediators: A systematic review and meta-analysis of clinical trials. Eur. J. Nutr., 2020, 59(5), 1803-1813. doi: 10.1007/s00394-019-02123-0 PMID: 31679041
  126. Anderson, G.; Reiter, R.J. Melatonin: Roles in influenza, COVID-19, and other viral infections. Rev. Med. Virol., 2020, 30(3), e2109. doi: 10.1002/rmv.2109 PMID: 32314850
  127. Begum, R.; Mamun-Or-Rashid, A.N.M.; Lucy, T.T.; Pramanik, M.K.; Sil, B.K.; Mukerjee, N.; Tagde, P.; Yagi, M.; Yonei, Y. Potential therapeutic approach of melatonin against omicron and some other variants of SARS-CoV-2. Molecules, 2022, 27(20), 6934. doi: 10.3390/molecules27206934 PMID: 36296527
  128. Alizadeh, N.; Dianatkhah, M.; Alimohamadi, Y.; Moradi, H.; Akbarpour, S.; Akrami, M.; Mansouri, F.; Faraji, N.; Rezaie, Z.; Alizadeh, M.; Hosamirudsari, H. High dose melatonin as an adjuvant therapy in intubated patients with COVID-19: A randomized clinical trial. J. Taibah Univ. Med. Sci., 2022, 17(3), 454-460. doi: 10.1016/j.jtumed.2022.04.012 PMID: 35581997
  129. Minich, D.M.; Henning, M.; Darley, C.; Fahoum, M.; Schuler, C.B.; Frame, J. Is melatonin the "next vitamin D"?: A review of emerging science, clinical uses, safety, and dietary supplements. Nutrients, 2022, 14(19), 3934. doi: 10.3390/nu14193934 PMID: 36235587
  130. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Moher, D. Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. J. Clin. Epidemiol., 2021, 134, 103-112. doi: 10.1016/j.jclinepi.2021.02.003 PMID: 33577987
  131. Hasan, Z.T.; Atrakji, D.M.Q.Y.M.A.A.; Mehuaiden, D.A.K. The effect of melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients. Int. J. Infect. Dis., 2022, 114, 79-84. doi: 10.1016/j.ijid.2021.10.012 PMID: 34653660
  132. Mousavi, S.A.; Heydari, K.; Mehravaran, H.; Saeedi, M.; Alizadeh-Navaei, R.; Hedayatizadeh-Omran, A.; Shamshirian, A. Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J. Med. Virol., 2022, 94(1), 263-271. doi: 10.1002/jmv.27312 PMID: 34460132
  133. Farnoosh, G.; Akbariqomi, M.; Badri, T.; Bagheri, M.; Izadi, M.; Saeedi-Boroujeni, A.; Rezaie, E.; Ghaleh, H.E.G.; Aghamollaei, H.; Fasihi-ramandi, M.; Hassanpour, K.; Alishiri, G. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, double-blind clinical trial. Arch. Med. Res., 2022, 53(1), 79-85. doi: 10.1016/j.arcmed.2021.06.006 PMID: 34229896
  134. Alizadeh, Z.; Keyhanian, N.; Ghaderkhani, S.; Dashti-Khavidaki, S.; Shokouhi, S.R.; Pourpak, Z. A pilot study on controlling coronavirus disease 2019 (COVID-19) inflammation using melatonin supplement. Iran. J. Allergy Asthma Immunol., 2021, 20(4), 494-499. doi: 10.18502/ijaai.v20i4.6959 PMID: 34418903
  135. Lan, S.H.; Lee, H.Z.; Chao, C.M.; Chang, S.P.; Lu, L.C.; Lai, C.C. Efficacy of melatonin in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. J. Med. Virol., 2022, 94(5), 2102-2107. doi: 10.1002/jmv.27595 PMID: 35032042
  136. Mazza, M.G.; Palladini, M.; Poletti, S.; Benedetti, F. Post-COVID-19 depressive symptoms: Epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs, 2022, 36(7), 681-702. doi: 10.1007/s40263-022-00931-3 PMID: 35727534

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers